A spike in demand for anxiety and depression drugs has led to shortages of some forms of the commonly used antidepressant Zoloft and its generic, sertraline.
The same shortages were reported among companies that make sertraline. Accord Healthcare, Inc. said it's unable to obtain the active ingredient for the drug"due to the impacts caused by COVID-19." The company estimated the shortage will last 60 days. The shortages follow a 21 percent rise in the number of prescriptions filled per week between mid-February and mid-March for medicines to treat anxiety, depression and insomnia, according to Express Scripts, a prescription benefit plan provider. The company said the increase peaked the week of March 15, just after the World Health Organization declared COVID-19 a pandemic.
Story continuesThe survey, which included responses from 1,468 adults, found 13.6 percent reported psychological distress in April 2020, up from 3.9 percent surveyed in 2018.The increase was most notable among Hispanics, adults under age 30 and people in low-income households.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
‘You could see the train wreck coming’: Inexperienced, dubious companies among many aiming to cash in on coronavirus antibody testsBuyer beware? Coronavirus antibody tests approved for sale by the FDA include companies with little or no background in medical testing. One sells vape pens, another male enhancement powders.
Source: USATODAY - 🏆 100. / 63 Read more »
FDA extends review of Novartis's OfatumumabNovartis AG said late Tuesday that the U.S. Food and Drug Administration has extended its review of the supplemental biologics license application for ofatumumab. The Swiss drug giant said regulatory action is expected in the U.S. in September 2020, anticipating approval for the targeted B-cell therapy for patients with relapsing multiple sclerosis in Europe by the second quarter of 2021.
Source: MarketWatch - 🏆 3. / 97 Read more »
Hype and science collide as FDA tries to rein in 'wild West' of COVID-19 blood testsThe FDA is trying to rein in the chaos it created by allowing companies to flood the market with COVID-19 antibody tests of questionable accuracy.
Source: latimes - 🏆 11. / 82 Read more »
At-Home SAT Off the Table for This Year, College Board SaysThe College Board said it won’t pursue plans to offer an at-home version of the SAT this year and warned in-person test dates are already filling up, complicating its efforts to make the exam accessible to rising high school seniors. Why is that stupid test still around. It tortured too many of my classmates for absolutely no reason 21 years ago. 😂 The college board has been such a trainwreck. Can’t get SAT dates or registration right, their system freezes during AP tests, etc. They have one job, to facilitate testing and reporting, and they can’t do it. “Scores” of colleges will not be requiring the SAT for admission this year, according to . So why is Michigan mandating this and other tests for high school students this Fall? priorities
Source: WSJ - 🏆 98. / 63 Read more »